Use of Bupropion in the Management of Negative Symptom Schizophrenia: A Case Series

Cureus. 2022 Mar 26;14(3):e23518. doi: 10.7759/cureus.23518. eCollection 2022 Mar.

Abstract

Antipsychotic treatment has been documented as the mainstay for the management of schizophrenia. Evidence in literature has suggested that the management of negative symptoms of schizophrenia continues to be a treatment challenge. Therefore, residual negative symptoms can become more pervasive and visible after the treatment of positive symptoms, leading to an impaired marked deficit in the vital daily functions of patients. We present a case series of three patients with a past psychiatric history of schizophrenia who presented to the psychiatric emergency with acute symptoms of schizophrenia. Following antipsychotic treatment, all these patients showed improvement of positive symptoms, however, profound negative symptoms of schizophrenia became visible. The negative symptoms include anhedonia, amotivation, alogia, affective flattening, and passive social withdrawal. We added bupropion to manage the negative symptoms, and all three patients achieved a good treatment response. This case series suggests that the anti-depressive effects of bupropion might be a valuable treatment option in the treatment of negative symptoms of schizophrenia.

Keywords: adjunct treatment; bupropion; case report series; negative symptoms; panss score; primary negative symptoms; residual; schizophrenia; secondary negative symptoms.

Publication types

  • Case Reports